TENTH ANNIVERSARY BULLETIN

Our Tenth Anniversary is a time to celebrate our achievements. Today, we are the most advanced depression research and awareness nonprofit organization in the United States.

MAJOR RESEARCH ADVANCES FROM OUR DEPRESSION TASK FORCE

Our team of eight pioneers in brain science have made undeniable progress through research grants funded by HDRF.

Research Advance # 1

The Depression Task Force has identified several gene families that may be key to unlocking the mystery of depression.

How?
The same suspect gene clusters continue to show up consistently in tests on animal models and samples of human tissue.

Why is that important?
Our scientists pinpointed these gene targets from literally thousands of potential genes by converging data from several different studies in our powerful Data Center. Using the most advanced computer technology in the world, they found noticeable overlaps in the vast data.

What’s next?
The scientists will collaborate to reveal what role the genes play in key mood circuits involved in depression. Their discoveries promise to open new pathways to develop novel treatments for depression.

continued on page 2
Research Advance #2
Our scientists have begun a major study on how traumatic environments can cause physical changes in the brain that lead to depression.

How?
Our scientists are using a breakthrough new technology that allows them to track chemical changes in genes when the brain is subjected to high doses of stress.

Why is this important?
This new technology will shed light on how environmental stressors might affect the activity of genes, brain cells and brain circuits involved in depression.

What’s next?
We have long known from broad studies on whole populations that children who grow up in abusive environments are more vulnerable to stress and resulting depression later in life. But why? How can traumatic environments literally become embedded in the biology of an individual? The new technology will help our scientists map the corrosive trail a big stressor can leave behind in the brain, ultimately revealing precise ways we can intervene to reverse the damage.

Research Advance #3
50% of depression patients do not respond to existing medications. The Depression Task Force is confronting the problem of treatment resistance head on.

How?
Our scientists have developed groundbreaking animal models of treatment resistance in the laboratory. Lack of these models has been holding the field back for decades.

Why is this important?
These new models allow our scientists to understand the brain biology and genetics associated with treatment resistance. Our scientists can also test new candidate drugs to see if they work when traditional medications (like the SSRIs) stop working, or fail to work in the first place.

What’s next?
The Depression Task Force is laser-focused on several new antidepressant drug candidates that show encouraging results in the laboratory. We will continue to update you as the research unfolds in 2016!
MEET AN HDRF NEUROSCIENTIST

HDRF Depression Task Force member Dr. Michael Meaney is Professor of Psychiatry and Neurology at McGill University.

Dr. Meaney is a world-acclaimed expert in epigenetics – the study of how the environment alters the brain’s chemistry. His particular interest is in how maternal care shapes emotional and cognitive development. Here Dr. Meaney explains how new technology developed at McGill will propel the next research breakthroughs of the Depression Task Force.

Today, a key part of depression research is identifying genes potentially at the root of depression. These genes are identified and tested in animal models. However, to date we have not had the technology to get a thorough grasp of how the genes work in living animal models.

At McGill we’ve developed neuro-imaging technology that allows us to view the brain of a living animal while we simultaneously test genes. We can actually observe brain circuits changing in real time after we trigger the gene to change with a drug or stress hit from the environment. Finally we can solve huge problems like why some people respond to existing SSRIs and others don’t. The ability to see the living brain in such detail will reveal clues that can fuel dramatic advances in the field.

IN THE NEWS
We’re thrilled to announce that The New Yorker has named a recent HDRF-funded study as one of the six most interesting psychology findings of the year.

Dr. Huda Akil, Chair of our acclaimed Depression Task Force, and her lab at UMich have identified a brain protein that seems to play a key role in depression. The protein – Fibroblast Growth Factor 9 – is part of a family of molecules that serve to stimulate and regulate the growth and activity of nerve cells in the brain.

Dr. Akil’s study shows that levels of FGF9 are concentrated at a high level in depressed adults. This finding could lead to new strategies for drug treatment.

MEET AN HDRF DONOR

Kristen Krusen is an investment professional and mother of two who recently joined the prestigious Chairman’s Council of top donors.

HDRF’s Chairman’s Council recognizes donors who give $10,000 or more annually to advanced research. A supporter since 2008, Krusen has been excited to see her investment drive tangible change.

I support HDRF because it has really broken through the barrier of stigma. There are many accomplished, influential people with great lives that go through this illness, or know someone struggling with it, and that’s okay.

It doesn’t make you less of a person. HDRF shows that with the speakers at its annual events, the second reason I give is HDRF’s research team. HDRF got the best minds together – and that is unique.

I’ve never seen research executed this way. Breaking down silos and putting the best researchers together – that approach has to be exponentially more powerful. I feel that every dollar I give can make a difference. It’s a privilege to be involved.

HDRF BOARD OF DIRECTORS
Audrey Gruss, Chairman
Harold W. Koenigsberg, M.D.
Robert Michels, M.D.
Steven P. Roose, M.D.
William T. Speck, M.D.

DEPRESSION TASK FORCE
Huda Akil, Ph.D.
University of Michigan, DTF Chair
Joshua Gordon, M.D., Ph.D.
New York State Psychiatric Institute & New York Presbyterian Hospital
René Hen, Ph.D.
Columbia University
Jonathan Javitch, M.D., Ph.D.
Columbia University
Helen S. Mayberg, M.D.
Emory University
Bruce McEwen, Ph.D.
Rockefeller University
Michael Meaney, Ph.D.
Douglas Institute & McGill University
Eric Nestler, M.D., Ph.D.
Mount Sinai School of Medicine
HOPE LUNCHEON SEMINAR
NOVEMBER 10, 2015

“Alcoholism and Depression: Dual Diagnosis, Dual Treatment”

Our sold-out Ninth Annual HOPE event honored Academy Award-nominated actress, writer and mental health advocate Mariel Hemingway, as well as Caron Treatment Centers, who are leaders in the field of addiction treatment. Multi-platinum artist and actress Demi Lovato was also honored as a HOPE Ambassador for a New Generation. Noted experts included Dr. Charles O’Brien, Founding Director of the Center for Studies in Addiction at the University of Pennsylvania.

Honoree Mariel Hemingway moved the audience with her personal remarks. “I tell my story because it’s not a unique story,” she said. “Although I come from one of the most famous American families, I grew up in a world of depression, addiction, and alcoholism. What people don’t understand is that depression is a brain problem and a life problem, and it needs to be talked about.”

MESSENGERS OF HOPE

In our media-oriented culture, one of the strongest ways to raise awareness about depression is through the power of celebrity communication. HDRF thanks all the public figures who have spoken at our events over the past ten years including Lorraine Bracco, Terry Bradshaw, Candace Bushnell, Richard Dreyfuss, Dominick Dunne, Linda Hamilton, Jay McInerney, David O’Russell, Brooke Shields and Callie Thorne.

HELP SUPPORT HDRF

100% of all donations go directly to research leading to a better diagnosis, new treatments and prevention of depression and its related mood and emotional disorders.

HDRF is a nonprofit 501(c)(3) public charitable organization. All donations are tax-deductible to the fullest extent of the law.

For more information, please contact:

New York HDRF
40 West 57th Street, Ste. 1440
New York, NY 10019
Phone: 212.676.3200
Fax: 212.676.3219
Email: hdrf@hopefordepression.org

Palm Beach HDRF
777 S. Flagler Drive, Ste. 801E
West Palm Beach, FL 33401
Phone: 561.515.6454
Fax: 561.514.3520
Email: hdrf@hopefordepression.org

visit us at:
www.hopefordepression.org

SAVE THE DATE!

WALK OF HOPE TO DEFEAT DEPRESSION
Saturday, July 30, 2016
Southampton, NY

TENTH ANNIVERSARY HOPE LUNCHEON SEMINAR
Tuesday, November 15, 2016
The Plaza Hotel